Use of All-Transretinoic Acid (ATRA)+ Arsenic Trioxide (ATO) To Eliminate or Minimize Use of Chemotherapy (CT) in Untreated Acute Promyelocytic Leukemia (APL).

EH Estey, G Garcia-Manero, A Ferrajoli, S Faderl… - Blood, 2004 - Elsevier
Current therapy cures most patients (pts) with newly diagnosed APL. Therefore, by analogy
to childhood acute lymphoblastic leukemia, focus reduction of therapy-associated toxicity
appears appropriate. Such reduction implies less reliance on anthracyclines, which can,
rarely but not inconsequentially, cause sepsis, myelodysplastic syndromes, and
cardiotoxicity. An obstacle to eliminating anthracylines is the belief that ATRA-induced
remissions are transient, unless anthracyclines are also given. We examined whether …
Save Cite Cited by 5 Related articles All 2 versions

[CITATION][C] Use of all-transretinoic acid (ATRA) plus arsenic trioxide (ATO) to eliminate or minimize use of chemotherapy (CT) in untreated acute promyelocytic …

EH Estey, G Garcia-Manero, A Ferrajoli, S Faderl… - Blood, 2004 - hero.epa.gov
Use of all-transretinoic acid (ATRA) plus arsenic trioxide (ATO) to eliminate or minimize use of
chemotherapy (CT) in untreated acute promyelocytic leukemia (APL) | Health & Environmental
Research Online (HERO) | US EPA Jump to main content US EPA United States Environmental
Protection Agency Search Search Main menu Environmental Topics Laws & Regulations About
EPA Health & Environmental Research Online (HERO) Contact Us Print Feedback Export to
File Search: HERO ID 2812051 Reference Type Journal Article Title Use of all-transretinoic …
Save Cite Cited by 5 Related articles Cached